GLP's ⏱ Half-life: ~10-30 minutes Experimental

Peptide YY

Peptide YY (PYY / Peptide Tyrosine Tyrosine)

Updated March 30, 2026

Evidence at a Glance

Regulatory statusExperimental
Endogenous gut hormone; no approved PYY drug; analogs (PYY1875, NN9748) in Phase 1/2
Human evidenceModerate
Animal evidenceExtensive

Peptide YY is an endogenous satiety hormone whose appetite-suppressing effects are documented in human infusion studies, but no PYY-based product is approved and longer-acting analogs remain in early-phase (Phase 1/2) obesity trials.

What the research does not support

  • There is no approved Peptide YY drug anywhere in the world for weight loss or any indication.
  • Native PYY has a very short half-life and its research effects come from controlled infusions, not from self-administered injections.
  • The obesity data driving interest are for engineered analogs (e.g. PYY1875) still in Phase 1/2, not the native peptide sold as research material.
  • It is not a substitute for or equivalent to GLP-1 medications, though it is being studied as an add-on to them.
Half-Life
~10-30 minutes
Purity
≥95%
Mol. Weight
4,049.55 Da
Form
Lyophilized powder

What is Peptide YY?

Peptide YY is a key satiety hormone released from the gut after eating. It plays a central role in the “gut-brain axis” that controls appetite. Research interest centers on its potential as a therapeutic target for obesity, either through direct administration or by enhancing endogenous PYY release through dietary interventions.

Dosage Information (Research Use)

Research doses: IV infusion at 0.8 pmol/kg/min in clinical studies. No standardized subcutaneous dosing established. Research compound only.

Reconstitution & Handling

Reconstitute with sterile water per manufacturer instructions.

Half-Life & Pharmacokinetics

~10-30 minutes

Reported Observations in Literature

Nausea at higher doses, transient increase in heart rate, abdominal discomfort. Generally well-tolerated in research settings at physiological doses.

Key Research References

  • Batterham RL et al. “Gut hormone PYY3-36 physiologically inhibits food intake.” Nature. 2002;418:650-4

How Peptide YY Works

Peptide YY (PYY) is released from intestinal L-cells after meals, acting on Y2 receptors in the arcuate nucleus of the hypothalamus to suppress appetite. PYY3-36, the primary circulating form, crosses the blood-brain barrier and directly inhibits NPY/AgRP neurons while activating POMC/CART neurons. It also slows gastric emptying and reduces gastric acid secretion.

Research Applications

🔬 Obesity and weight management
🔬 Appetite regulation and satiety
🔬 Type 2 diabetes and metabolic syndrome

Research Findings

Infusion studies show PYY3-36 reduces caloric intake by ~30% in both lean and obese individuals. Obese subjects have lower baseline PYY levels, suggesting a physiological role in obesity. Combination approaches with GLP-1 agonists show additive appetite suppression.

Dosage & Administration

Research doses: IV infusion at 0.8 pmol/kg/min in clinical studies. No standardized subcutaneous dosing established. Research compound only.

Safety & Side Effects

Nausea at higher doses, transient increase in heart rate, abdominal discomfort. Generally well-tolerated in research settings at physiological doses.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Molecular Weight 4,049.55 Da
Half-Life ~10-30 minutes
Purity ≥95%
Form Lyophilized powder
Storage Lyophilized: -20°C. Reconstituted: 2-8°C.

Key Research References

  • Batterham RL et al. "Gut hormone PYY3-36 physiologically inhibits food intake." Nature. 2002;418:650-4

Related Peptides

View all →
Pemvidutide
GLP's
GLP-1/glucagon dual agonist designed for better body composition — promoting fat loss while preserving muscle mass during weight…
View Profile →
Pramlintide
GLP's
FDA-approved synthetic amylin analog that complements insulin therapy by slowing gastric emptying, reducing glucagon, and enhancing satiety.
View Profile →
CagriSema
GLP's
Fixed-dose combination of amylin analog cagrilintide with semaglutide for enhanced weight management research.
View Profile →